CDR Ltd Founded by Professor Keith Wesnes in 1986, CDR now employs some 50 staff in the UK, USA and Australia, and is the world's leading provider of automated cognitive function assessment in clinical trials. CDR's proprietary cognitive assessment system can be administered to virtually any patient population in any environment and provides rapid, sensitive and highly reliable assessments of the core domains of cognitive function. The CDR system is used throughout the drug development process, from first-to-man trials to large worldwide Phase IV trials. The CDR system has been used in over 900 trials is documented to ICH GCP and FDA 21 CFR part 11 standards. CDR has twice received the most prestigious business accolade in the UK, the Queen's Awards for Enterprise. CDR offers a full, customised cognition assessment service, implementing assessments into any trial design to virtually any timeline, providing support and consultancy throughout the study and providing full analysis, interpretation and reporting of study data.

CeNeS Ltd  novel drugs for pain, anaesthesia and neurology

Cerebricon Ltd.  pre-clinical contract research

Eli Lilly and Company Limited   
Innovation in Medicine

Enkam  

H. Lundbeck A/S   

Hope Hospital, Salford  

ICON Development Solutions  
Clinical Pharmacology research (Phase I and Phase IIa) in healthy volunteers and patients Pop PK and PK/PD modelling Pharmacometrics services Bioanalytical laboratory support Clinical Pathology support Regulatory Affairs services Strategic Drug Development consultancy

Karolinska Institute  Prof Christian Spenger

Kings College London  

National Board of Forensic Medicine   

Pharmidex Pharmaceutical Services Ltd  CNS drug discovery and development

Roskilde University Center  

Schizodetect  

Solace Pharmaceuticals  discovering and developing innovative treatments for pain
Interested in discovering and developing medicines for treating pain, acute or chronic. Active drug development programme in glial modulation and discovery programme in modulating BH4 levels in response to nerve injury or inflammation. Patents to cover the intellectual property described above. discovering and developing innovative treatments for pain

St Georges Hospital  

UK Trade & Investment  

University of Bristol  
My current research is focussed on the using electrophysiological techniques to investigate the effects of naturally occurring stimulation patterns on synaptic transmission at the hippocampal mossy fibre synapse. I am conducting field recordings from the CA3 region of the hippocampus while playing back in vivo granule cell firing patterns. I am investigating which patterns of activity give rise to long-term changes in synaptic efficacy at this synapse. My previous experience includes whole-cell patch-clamp and perforated patch techniques.

University of Copenhagen  

University of Manchester  

Wolfson Imaging Centre   

Lin Bateson  BioPartner.co.uk
Lin is the project manager for the UK-MV Bioscience Alliance, organising this workshop.

To contact these delegates, send your enquiry to: info@biosciencealliance.eu